Kailera Therapeutics completes enrollment in KaiNETIC Phase 3 ribupatide obesity trials

Kailera Therapeutics completed enrollment in its global Phase 3 KaiNETIC program testing once-weekly ribupatide injection, with topline data expected mid-2028.